Cancer/Oncology

It's more than a test. 

It's informed clinical decision making.

 

For in vitro diagnostic use.

Football banner image
Football banner image
Football banner image

Biomarkers can play a crucial role throughout a patient's cancer journey

Biomarkers can assist with risk stratification, surveillance and diagnosis, as well as predicting and monitoring treatment response or assessing disease progression and recurrence.1 This information should be utilized alongside existing clinical and diagnostic findings to select appropriate treatment interventions for each patient. 

THE ROLE OF BIOMARKER ASSAYS FROM ABBOTT ACROSS A PATIENT’S CANCER JOURNEY


 

LEVERAGING ALGORITHMS TO HELP IMPROVE RISK-PREDICTION ACCURACY

With one out of every two people expected to get cancer during their lifetime there is a clear need to optimize diagnostic solutions to tackle key challenges in oncology management.2 

A rising number of tests combine the insights derived from two or more biomarkers into an algorithm to generate a result.3 These are known as multianalyte assays with algorithmic analysis (MAAAs). This combination improves performance compared to using single biomarkers.3 

ASSAYS ENGINEERED TO PROVIDE RELIABLE ASSISTANCE IN CANCER MANAGEMENT

Abbott offers a wide variety of assays to assist in the risk-stratification, diagnosis and management for many types of cancers including, colon, liver, ovarian, breast, pancreatic, testicular, gastrointestinal, lung and prostate cancer

The oncology solutions from Abbott can help you reduce laboratory operational costs while maintaining the quality standards necessary to have a meaningful positive impact to the quality and cost of health care.

Visit our individual disease state pages to discover more about biomarker solutions

Stay informed banner image
Stay informed banner image
Stay informed banner image
Core laboratory menu
Register or login to your account to view assay specific package inserts for intended use and important safety information.

 

Some assays may not be available on all platforms.

 

Cancer
AFP
Beta2 Microglobulin
CA 125 II
CA 15-3
CA 19-9 (CA 19-9 XR)
CEA
CYFRA 21-1
HE-4
Immunoglobulin A (IgA)
Immunoglobulin E (IgE)
Immunoglobulin G (IgG)
Immunoglobulin M (IgM)
Kappa Light Chain
Lambda Light Chain
Pepsinogen I
Pepsinogen II
PIVKA-II
ProGRP
PSA, Free
PSA, Total
SCC
Explore

Knowledge Center

Find the latest information in laboratory science, therapeutic areas and Abbott innovation.

Customer Portal

Receive exclusive benefits and resources when you register to access to the Customer Portal.

Contact Us

Abbott's Representatives are ready to offer support, gather feedback, and answer any questions.

References
  1. Whitaker K. 2020. Earlier diagnosis: the importance of cancer symptoms. Lancet Oncol. 21:pp6–8. 
  2. NHS. 2022. Cancer Overview. Available at: https://www.nhs.uk/conditions/cancer/. Last accessed: 31 July 2023.
  3. The Economist Intelligence Unit., 2021. Improving cancer risk assessment and prognosis: the role of Multianalyte Assays with Algorithmic Analyses. Available at: https://impact.economist.com/perspectives/sites/default/files/images/abbott-3_maaas_report_v4_2.pdf.